Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antiba…
Biotechnology
US, Bridgewater [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Insmed Incorporated (INSM) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,606.87 | 879.83 | 213.80 | 205.55 | 43.78 | 0.00 | 19.8256 | -0.36 | -1.0269 | -23.3515 | -0.09 | -0.08 | 7.2602 | - - | ||
| Maximum | - - | - - | - - | 441,252.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.02 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Ultragenyx Pharmaceutical Inc. RARE | 46.96 | 0.56 1.21% | 92 vs. 723 | 4,336.00 | 108.00 | -170.00 | -203.00 | -3,558.00 | -2.0300 | -5.7986 | 0.0000 | 0.7576 | -1.5683 | -1.2169 | -0.1306 | 2.1127 | 92.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 26.93 | -0.56 -2.02% | 351 vs. 2,868 | 3,350.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| Halozyme Therapeutics, Inc. HALO | 44.95 | -0.81 -1.77% | 231 vs. 1,580 | 5,718.00 | 195.00 | 76.00 | 125.00 | 167.00 | 0.6100 | 17.0691 | 0.0000 | 0.7647 | 0.3922 | 0.4321 | 0.0417 | 5.0088 | 127.00 | ||
| Insmed Incorporated INSM | 71.94 | -0.73 -1.00% | 227 vs. 1,651 | 12,871.00 | 75.00 | -157.00 | -188.00 | -3,603.00 | -1.0600 | -6.3128 | 0.0000 | 0.7521 | -2.0807 | 0.3380 | -0.1355 | 1.5038 | 178.00 | ||
| Revolution Medicines, Inc. RVMD | 57.69 | 0.62 1.09% | 209 vs. 1,174 | 9,704.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 | ||
| Akero Therapeutics, Inc. AKRO | 30.66 | 0.03 0.08% | 43 vs. 551 | 2,140.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
| Blueprint Medicines Corporation BPMC | 95.49 | 0.68 0.72% | 109 vs. 620 | 6,066.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.